IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6724-6733

  Gherardi, M Magdalena ^a   Ramirez, Juan C ^a   Rodríguez, Dolores ^a   Rodríguez, Juan R ^a   Sano, Gen Ichiro ^b   Zavala, Fidel ^b   Esteban, Mariano ^a,c  

^a CSIC   (Spain)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 12; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP160; HIV-1; IMMUNITY, CELLULAR; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; SPLEEN; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0033151996     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. World Health Organization. 1980. The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. History of International Public Health, No. 4. World Health Organization, Geneva.
2. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341.
3. Brochier, B., F. Costy, and P. P. Pastoret. 1995. Elimination of fox rabies from Belgium using recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 46:269.
4. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, W. R. Elkins, W. G. Alvord, D. Montefiori, et al. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol 70:3741.
5. Belyakov, I. M., L. S. Wyatt, J. D. Adlers, P. Earl, C. D. Pendelton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:8264.
6. Wyatt, R., and J. Sodrosky. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884.
7. Connor, R. I., B. T. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neuman, S. H. Vermund, J. Mestecky, S. Jackson, et al. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunits vaccines. J. Virol. 72:1552.
8. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. Mcleod, W. Borkowsky, C. Fathing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
9. Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267.
10. Rowland-Jones, S., R. Tan, and A. J. McMichael. 1997. The role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:277.
11. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, et al. 1995. HIV-1 specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59.
12. Buseyne, F., M. Bugard, J. P. Teglas, E. Bui, C. Rouzioux, M. J. Mayaux, S. Blanche, and Y. Riviere. 1998. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. AIDS Res. Hum. Retroviruses 16:1435.
13. + nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1:1167.
14. Trinchieri, G. 1994. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
15. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T-helper 1-directed antitumor response. J. Immunol. 153:1997.
16. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16:34.
17. Trinchieri, G. 1998. Immunobiology of interleukin-12. Immunol. Res. 17:269.
18. Gazzinelli, R. T., N. A. Giese, and H. C. Morse III. 1994. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J. Exp. Med. 180:2199.
19. Ramshaw, I. A., A. J. Ramsay, G. Karupiah, M. S. Rolph, S. Mahalingam, and J. C. Ruby. 1997. Cytokines and immunity to viral infections. Immunol. Rev. 159:119.
20. Rodríguez, J. F., D. Rodríguez, J. R. Rodríguez, E. B. McGowan, and M. Esteban. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA 85:1667.
21. Rodríguez, D., J. R. Rodríguez, J. F. Rodríguez, D. Trauber, and M. Esteban. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinants viruses. Proc. Natl. Acad. Sci. USA 86:1287.
22. Dallo, S., and M. Esteban. 1987. Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159:408.
23. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23:1094.
24. Carroll, M. W., and B. Moss. 1995. E. coli β-glucoronidase (GUS) as a marker for recombinant vaccinia viruses. BioTechniques 19:352.
25. Rodríguez, J. R., C. Risco, J. L. Carrascosa, M. Esteban, and D. Rodríguez. 1997. Characterization of early stages in vaccinia virus membrane biogenesis: implications of the 21-kilodalton protein and a newly identified 15-kilodalton envelope protein. J. Virol. 71:1821.
26. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45.
27. Hogan, S. P., P. S. Foster, X. Tan, and A. J. Ramsay. 1998. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur. J. Immunol. 28:413.
28. Shida, H., Y. Hinuma, M. Hatanaka, M. Morita, M. Kidokoro, K. Suzuky, T., Maruyama, F. Takahashi, M. Sujimoto, R. Kitamura, et al. 1988. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J. Virol. 62:4474.
29. Karupiah, G., B. Coupar, I. Ramshaw, D. Boyle, R. Blanden, and M. Andrew. 1990. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol. Cell Biol. 68:325.
30. Gately, M. K., A. G. Wolitzky, and P. M. Quinn. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol. 143:127.
31. Bloom, E. T., and J. A. Horvath. 1994. Cellular and molecular mechanisms of the IL-12 induced increased in allospecific murine cytolytic T-cell related decline in CTL. J. Immunol. 152:4242.
32. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Auget. 1993. Immune response in mice that lack the interferon-γ receptor. Science 259:1742.
33. + T cells is dependent on interferon-γ. Lymphokine Cytokine Res. 10:353.
34. Gherardi, M. M., and M. Esteban. 1999. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17: 1074.
35. Snaper, C. M., and W. E. Paul. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944.
36. Perkus, M. E., J. Tartaglia, and E. Paoletti. 1995. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukocyte Biol. 58:1.
37. Myagkikh, M., S. Alipanah, P. D. Markham, J. T. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxviruses HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985.
38. Giavedoni, L. D., L. Jones, M. B. Gardner, H. L. Gibson, C. T. Lee, P. J. Barr, and T. Yilma. 1992. Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and γ interferon are attenuated for nude mice. Proc. Natl. Acad. Sci. USA 89:3409.
39. Car, B. D., V. M. Eng, B. Schnyeder, M. LeHir, A. N. Shakhov, G. Woerly, S. Huang, M. Aguet, T. D. Anderson, and B. Ryffel. 1995. Role of interferon y in interleukin 12-induced pathology in mice. Am. J. Pathol. 147:1693.
40. Coutelier, J. P., J. Van Broeck, and S. F. Wolf. 1995. Interleukin-12 gene expression after viral infection in the mouse. J. Virol. 69:1955.
41. Kanangat, S., J. Thomas, S. Gangappa, J. Sam Babu, and B. T. Rouse. 1996. Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. J. Immunol. 156:1110.
42. Orange, J. S., and C. A. Biron. 1996. An absolute and restricted requirement for IL-12 in natural killer cell IFN-γ production and antiviral defense. J. Immunol. 156:1138.
43. Ozmen, L., M. Aguet, G. Trinchieri and G. Garotta. 1995. The in vivo antiviral activity of interleukin-12 is mediated by y interferon. J. Virol. 69:8147.
44. Carr, J. A., J. Rogerson, M. J. Mulqueen, N. A. Roberts, and R. F. G. Booth. 1997. Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J. Virol. 71:7799.
45. Monteiro, J., C. Harvey, and G. Trinchieri. 1998. Role of interleukin-12 in primary influenza virus infection. J. Virol. 72:4825.
46. Schijns, V. E. C., B. L. Haagmans, C. M. H. Wierda, B. Kruithof, I. A. F. M. Heijnen, G. Alber, and M. C. Horzinek. 1998. Mice lacking IL-12 develop polarized Th1 cells during viral infection. J. Immunol. 160:3958.
47. Ramsay, A. J., J. Ruby, and I. A. Ramshaw. 1993. The case of cytokines as effector molecules in the resolution of virus infection. Immunol. Today 14:155.
48. Melková, Z., and M. Esteban. 1994. Interferon-γ severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 198:731.
49. Melková, Z., and M. Esteban. 1995. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 155:5711.
50. Melková, Z., S. B. Lee, D. Rodríguez, and M. Esteban. 1997. Bcl-2 prevents nitric oxide-mediated apoptosis and poly (ADP-ribose) polymerase cleavage. FEBS Lett. 403:273.
51. Orange, J. S., S. F. Wolf, and C. A. Biron. 1994. Effects of L-12 on the response and susceptibility to experimental viral infections. J. Immunol. 152:1253.
52. Sharma, D. P., A. J. Ramsay, D. J. Maguire, M. S. Rolph, and I. A. Ramshaw. 1996. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia infection in vivo. J. Virol. 70:7103.
53. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Derosiers 1996. Vaccine protection by a triple deletion of simian immunodeficiency virus. J. Virol. 70:3724.
54. Benson, J., C. M. Chougnet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C. Gallo, M. Cranage, E. Paoletti, K. Limbach, et al. 1998. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251 dependence on route of challenge exposure. J. Virol. 72:4170.
55. Takashi, T., K. Hamajima, J. Fukushima, K. Q. Xin, N. Ishii, I. Aoki, Y. Ishigatsubo, K. Tani, S. Kawamoto, Y. Nitta, et al. 1997. Enhancement of cell-mediated immunity against HIV-1 induced coinoculation of plasmid encoded HIV-1 antigen with plasmid expressing IL-12. J. Immunol. 158:4008.
56. Ahlers, J. D., Dunlop N., D. W. Ailing, P. L. Nara, and J. A. Berzofsky. 1997. Cytokine in adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J. Immunol. 158:3947.
57. Kim, J. J., N. N. Triveldi, L. K. Nottingham, L. Morrison, A. Tsai, Y. Hu, S. Mahalingham, K. Dang, L. Ahn, N. K. Doyle, et al. 1998. Modulation of amplitude and direction of in vivo immune responses by coadministration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28:1089.
58. Kim, J. J., V. Ayyavoo, M. L. Bargarazzi, M. A. Chattergoon, K. Dang, B. Wang, J. D, Boyer, and D. B. Weiner. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol. 158:816.